Latest National Cancer Institute Stories
- Awarded phase II STTR grant of approximately $1.1 million from NIH to develop tumor activated prodrugs BOSTON, Sept.
Treatment designed to reduce pain and inflammation associated with radiation therapy to the lower bowel. Claremont, CA (PRWEB) September 27, 2014 Synedgen
Collaborative efforts with leading cancer centers to provide clinical test is supported CAMBRIDGE, Mass., Sept.
By the National Cancer Institute BETHESDA, Md., Sept. 24, 2014 /PRNewswire-USNewswire/ -- An African American man in his 60's has read about a new targeted therapy for lung cancer.
Contract Funds 3D Breast Cancer, 3D Brain Cancer Micro-Tumor Development GREENVILLE, S.C., Sept.
A collaborative study between researchers at the University of Colorado Cancer Center and the National Cancer Institute (NCI) published today in the journal Clinical Cancer Research takes an important
A new public-private partnership is committing $11.5 million towards transformational, theoretical biophysics that could have a significant impact on cancer research and treatment.
In the news release, Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S.
The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August
- An imitative word; an onomatopoetic word.